← All diseases Cancer

Multiple myeloma

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest level of evidence only (62)Meta-analysis (11)Treatment guideline (2)Systematic review (24)Randomized trial (16)Phase 3 study (9)Clinical trial (631)Review article (257)Early study (phase 1 or 2) (36)Case report (252)Laboratory or animal study (23)Commentary or editorial (45)Retracted Publication (4) Studies currently recruiting participants only (35)

Filter

Publications (1557)

• A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model. (2026/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Metabolic alterations in multiple myeloma and extramedullary disease- a novel niche of therapeutic targets. (2026/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Emerging roles of RNA m(6)A modification in multiple myeloma pathogenesis and treatment resistance (Review). (2026/04/01) ♡
• Vegetarian diets and cancer risk: pooled analysis of 1.8 million women and men in nine prospective studies on three continents. (2026/04/01) ♡
• Prognostic Effect of Sarcopenia and Nutritional Factors on Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Exploratory Study. (2026/04/01) ♡
• Fiber: A New Myeloma Prevention Approach with Abundant Positive Effects. (2026/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1. (2026/03/27) ♡
• Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience. (2026/03/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. On-target, off-tumor oral toxicities of talquetamab in heavily pretreated multiple myeloma. (2026/03/20) ♡
• A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone. (2026/03/19) ♡
• Clinical Determinants of Urinary Podocyte Biomarkers and Their Feasibility in Paraprotein-Related Kidney Disease. (2026/03/19) ♡
• Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma. (2026/03/14) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Kidney-Tonifying, Phlegm-Resolving, and Blood Stasis-Removing Therapy for Multiple Myeloma: Protocol for a Randomized Controlled Trial on Epigenetic and Immune Modulation. (2026/03/05) ♡
• Type 2 diabetes and risk of non-Hodgkin lymphoma and multiple myeloma: a pooled analysis. (2026/03/03) ♡
• Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16(+) NK cell-mediated cytotoxicity. (2026/03/03) ♡
• Three-decade trends in risk factor-attributable cancer burden in China: insights from the Global Burden of Disease Study 2023. (2026/03/01) ♡
• Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Skeletal health in the precursor stages of multiple myeloma: fracture risk and bone phenotypes in monoclonal gammopathy of undetermined significance and smouldering myeloma. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma. (2026/03/01) ♡
• Screening for multiple myeloma has low yield as part of a secondary osteoporosis screen. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application. (2026/03/01) ♡
• Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit. (2026/03/01) ♡
• Crystal-Storing Histiocytosis as a Red Herring in Multiple Myeloma. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. MRD in multiple myeloma: the clinical perspective. (2026/02/27) ♡
• Construction and validation of a nutritional status (CONUT)-based nomogram for predicting prolonged hematological toxicity in relapsed/refractory multiple myeloma after CAR-T cell therapy. (2026/02/23) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Neuronal metabolism role in ketogenic diet improvements in bortezomib-induced painful peripheral neuropathy mouse model. (2026/02/17) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis. (2026/02/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies. (2026/02/05) ♡
• Plant-based whole-food diets are feasible during autologous stem cell transplantation and are associated with dose-dependent microbiome modulation: Results from a pilot clinical trial. (2026/02/04) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Sarcopenia in Older Adults with Hematologic Malignancies: A Comprehensive Review of Epidemiology, Prognosis, and Interventions. (2026/02/03) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Triclonal Gammopathy in Multiple Myeloma with Bleeding Diathesis: A Case Report. (2026/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical and epidemiologic characteristics of hospitalized oncological patients with hypercalcemia: a longitudinal, multicenter study. (2026/02/01) ♡
• Systemic bone loss measured by routine CT is associated with increased pain, postural decompensation, and survival in multiple myeloma. (2026/02/01) ♡
• Feasibility assessment of an EHR-integrated research platform for prospective data collection in community oncology practice. (2026/01/28) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Septic Arthritis Secondary to Acupuncture in an Immunocompromised Patient With Multiple Comorbid Conditions. (2026/01/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches. (2026/01/22) ♡
• Thalidomide as a rescue protocol for treatment of multiple myeloma in dogs: preliminary data from a multicentre retrospective study. (2026/01/22) ♡
• Saudi experts statement on advancing multiple myeloma treatment: the evolving role of bispecific antibodies. (2026/01/21) ♡
• Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma. (2026/01/13) ♡
• Association between systemic immune-inflammatory markers and monoclonal gammopathy of undetermined significance in the elderly population: findings from the National health and nutrition examination survey. (2026/01/13) ♡
• Construction and validation of nomogram prediction model for anxiety and depression in chemotherapy patients with multiple myeloma. (2026/01/12) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies. (2026/01/12) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Headache as the initial symptom in two cases of multiple myeloma: a case report and literature review. (2026/01/12) ♡
• A nutritional index model for predicting resistance and prognosis in multiple myeloma following autologous stem cell transplantation. (2026/01/12) ♡
• Status and trends of early-onset cancers and their risk factors in China: population-based study. (2026/01/12) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: A case of heart failure recovery after non-ischemic cardiomyopathy following chimeric antigen receptor T-cell therapy. (2026/01/08) ♡
• m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis. (2026/01/07) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials. (2026/01/06) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Infection risks associated with daratumumab-containing regimens in multiple myeloma: a systematic review and meta-analysis. (2026/01/06) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis. (2026/01/06) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.